Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PRMT1 inhibitor GSK3368715

An orally available inhibitor of protein arginine N-methyltransferase 1 (PRMT1; Histone-arginine N-methyltransferase PRMT1; Interferon receptor 1-bound protein 4) with potential antineoplastic activity. Upon administration, GSK3368715 inhibits monomethylation and asymmetric dimethylation of arginine-bearing substrates, including histones, estrogen receptors, RNA-binding proteins, and numerous non-histone substrates catalyzed by PRMT1. This may inhibit tumor cell proliferation, migration, and invasion that is potentially driven by PRMT1 overexpression or dysregulation. PRMT1-mediated methylation plays a key role in the modulation of protein function, gene expression and cellular signaling. Dysregulation and overexpression of PRMT1 has been associated with a number of solid and hematopoietic cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:protein arginine methyltransferase 1 inhibitor GSK3368715
Code name:GSK 3368715
GSK-3368715
GSK3368715
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search